Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Humacyte (HUMA) Operating Expenses (2024 - 2025)

Humacyte has reported Operating Expenses over the past 2 years, most recently at $31.3 million for Q4 2025.

  • Quarterly results put Operating Expenses at $31.3 million for Q4 2025, up 11.45% from a year ago — trailing twelve months through Dec 2025 was $110.2 million (down 3.69% YoY), and the annual figure for FY2025 was $110.2 million, down 3.69%.
  • Operating Expenses for Q4 2025 was $31.3 million at Humacyte, up from $25.1 million in the prior quarter.
  • Over the last five years, Operating Expenses for HUMA hit a ceiling of $31.3 million in Q4 2025 and a floor of $23.7 million in Q1 2025.